GlaxoSmithKline PLC, a research-based pharmaceutical and healthcare company, said Thursday that it has made the decision not to pursue further worldwide development of Simplirix Herpes Simplex Vaccine, an experimental vaccine intended to prevent genital herpes disease in women.
Glaxosmithkline not to pursue further worldwide development of Simplirix